Actavis (NASDAQ:ACT): Current price $127.59
On Monday it was announced that Actavis will purchase Warner Chilcott in an all-stock transaction valued at roughly $8.5 billion. Once completed, the acquisition will form a global specialty pharmaceutical firm holding around $11 billion in combined annual revenue, and will create the number-three such company in the United States with about $3 billion in annual revenues, concentrated upon core therapeutic categories of Women’s Health, Gastroenterology, Urology, and Dermatology. The proposed deal was unanimously okayed by the boards of both Actavis and Warner Chilcott.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.